Track record · closed signal

Innoviva, Inc. (INVA) — closed signal from March 9, 2026

Near target Published before the outcome was known, scored automatically when the window closed on June 7, 2026 — +2.8% at the close.

Predicted vs. what happened

INVA price · publication thesis → realized outcomesplit-adjusted

$21.00 – $22.20Entry zone — fair-value band

$21.92Published — price the day we called it

$24.54Target — the price the thesis aimed for

$24.45Peak — highest point inside the window, not a realized return

$22.52Window close — end-of-window price, context only

What happened

Near target

Came within reach: 97% of the predicted growth at its peak, just short of the target.

At window close

+2.8%

realized, from the publication price to the last close inside the window

Peak gain

+11.6%

peak, from the publication price — not a realized return

S&P 500, same window

+9%

SPY over the identical days, dividend-adjusted

Window close

$22.52

last close inside the window, ended June 7, 2026

Peak price

$24.45

peak on April 20, 2026 — not a realized return

Days to target

—

The thesis — published March 9, 2026

Predicted growth

+12%

over the measurement window

Target price

$24.54

the price the thesis aimed for

Entry zone

$21.00 – $22.20

the fair-value band we waited for

Price at publication

$21.92

published March 9, 2026

Confidence

68%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Recent company news makes the stock less risky on the downside even though the price pattern has not fully turned positive. A higher analyst target, a new buyback, and a big cash balance make it easier for the stock to be revalued if investors start liking the commercial biotech story. Best bought in smaller chunks.

Primary drivers

New buyback reduces downside risk and shows discipline
Big cash balance gives the company flexibility
Analyst raising target improves short-term outlook
Revenue from products and royalties spreads risk

How it played out

INVA: target missed after an 11.6% peak gain

Lyra published INVA at $21.92 on March 9, 2026, with 12% expected growth over a short-term window. The thesis pointed to a new buyback, a big cash balance, a higher analyst target, and revenue from products and royalties that spread risk.

Inside the window, INVA rose to $24.45 on April 20, 2026, for an 11.6% peak gain. The target was $24.54. It never got there. The stock ended the window at $22.52 on June 7, 2026. The thesis mostly played out on price, but it missed the target.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All INVA signals